Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462836 | 0.95 | ALDH1A1 (0.64) | ALDH1A1TSHRCYP2D6KDM4EFDPS | |
| SCHEMBL14216877 | 0.95 | ALDH1A1 (0.64) | ALDH1A1TSHRCYP2D6KDM4EFDPS | |
| Hydrochloric Acid SCHEMBL5692430 | 0.94 | ALDH1A1 (0.63) | ALDH1A1TSHRCYP2D6KDM4EFDPS | |
| SCHEMBL4056455 | 0.94 | ALDH1A1 (0.59) | ALDH1A1TSHRKDM4EFDPSTDP1 | |
| SCHEMBL29038447 | 0.90 | ACHE (0.58) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 | |
| SCHEMBL29038431 | 0.89 | FDPS (0.57) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 | |
| SCHEMBL29570200 | 0.89 | ALDH1A1 (0.65) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 | |
| SCHEMBL29038405 | 0.89 | ACHE (0.59) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 | |
| SCHEMBL4048998 | 0.89 | ALDH1A1 (0.65) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5692356 | 0.88 | ALDH1A1 (0.64) | ALDH1A1TSHRKDM4EFDPSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283936-A | Substituted amino ether-containing 2, 2-dimethyl benzopyran derivative and salt or solvate thereof, preparation and application thereof, and composition | 沈阳药科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2020-10-22 | — | — | US | disclosed |
| US-9617227-B2 | Process of preparing a quinazoline derivative | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2017-04-11 | — | — | US | disclosed |
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2016-07-14 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| EP-2247596-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | Natco Pharma Limited (IN) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010076810-A2 | A PROCESS FOR THE PREPARATION OF GEFITINIB | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-07-08 | — | — | WO | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | disclosed |
| WO-2005070909-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GEFITINIB | NATCO PHARMA LIMITED (IN) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | ALDH1A1 2730/4885TSHR 571/4885CYP2D6 158/4885 |
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | ABL1, EGFR, KRAS | ALDH1A1 2355/4885TSHR 2894/4885CYP2D6 70/4885 |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | MAP7, NQO2, ABL1 | ALDH1A1 738/4885TSHR 4668/4885CYP2D6 6/4885 |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | PAH, NQO2, MAP7 | ALDH1A1 1252/4885TSHR 4729/4885CYP2D6 15/4885 |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | ALDH1A1 309/4885TSHR 4277/4885CYP2D6 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.